The monoclonal antibody therapy is now the first and only treatment approved for patients with IgG4-RD.

For decades, successful pharmaceutical manufacturing has been judged on scale. Nowadays, higher precedence is being given to speed, coping with complexity, and customization.

The Michael J. Fox Foundation for Parkinson’s Research and the Luxembourg National Research Fund have provided funding for two separate projects assessing Accure Therapeutics’ ACT-02 for the treatment of Parkinson’s disease.

A challenging biotech investment landscape is shaking up the industry and having a negative impact on multiple CDMOs in the space.

The radiopharmaceuticals CDMO will have a majority stake in Agilera Pharma, advancing its strategy of becoming a fully-integrated service provider in the radiopharmaceutical therapy sector.

Over the next five years, Novartis will be investing USD23 billion in 10 facilities, including seven new facilities.

Drug delivery companies — SHL Medical and Kindeva Drug Delivery — have formed a partnership to enhance SHL Medical’s Molly® autoinjector platform aimed at pharmaceutical and biotechnology companies.

CDMO, Suven Pharmaceuticals, aims to reach USD 1 bn in revenue by 2030, by investing in new facilities to increase production capacity and strengthen its capabilities in drug development and manufacturing to support global pharmaceutical clients.

Through analysis of historical vaccination program data, researchers have demonstrated a persistent link between the live-attenuated zoster vaccination and a lower incidence of dementia.

Advanced therapy medicinal products specialist CDMO, Porton Advanced, and clinical-stage biotech, Eureka Therapeutics, have entered a strategic collaboration to accelerate the development and commercialization of T-cell therapies for cancer treatment.

Biologics CDMO, Wheeler Bio, has successfully raised USD 35 mn in an oversubscribed Series A-1 funding round. The funds will help the company strengthen its biologics’ manufacturing capabilities, such as planning the development of a large-scale facility.

Canadian CDMO, Delpharm, has secured a USD 42 mn investment from the Canadian Government to enhance the production capacity of its injectables manufacturing facility in Montreal, Canada.

Curium, a global leader in nuclear medicine, has announced the acquisition of radiopharmaceutical company, Monrol, as the company aims to improve its position in the global nuclear medicine market,.

Novo Nordisk has entered into an exclusive global licensing agreement with Lexicon Pharmaceuticals for Lexicon’s promising drug candidate, LX9851, which targets gastrointestinal disorders.

Spanish CDMO, Esteve Química, is investing USD 100 mn to expand its U.S. manufacturing capabilities, focusing on increasing production capacity for high potency APIs (HPAPIs) amid increasing market demands for their use.

Innovation, science, and pharmaceutical services partner, Bend Bioscience, is expanding its Gainesville, Georgia facility with the addition of a commercial-scale spray dryer and a Gerteis drug granulation system.

US CDMO, Bionova Scientific, has selected New York CRO, Bionique Testing Laboratories, as its preferred provider for mycoplasma testing services in biologics manufacturing. The appointment will allow enhanced quality control processes for biologics production, ensuring the safety and efficacy of therapeutic products.

BioDuro, the global contract research, development and manufacturing (CRDMO) company, has opened a new state-of-the-art laboratory in Shanghai, China for the synthesis of high-potency APIs for the pharmaceutical industry.

CDMO partnerships are great when they are successful, but what happens when they falter? The complexity of modern outsourcing partnerships means that failure is often costly, with consequences that can ripple across timelines, budgets, and reputations.

Indian CDMO, Shilpa Medicare, has launched a 'hybrid' CDMO model at DCAT 2025. Focusing on oncology, the company will begin to offer both traditional CDMO services and ready-to-license novel formulations, allowing clients to leverage Shilpa's expertise without development risks or delays.